ClinicalTrials.gg
CompletedNCT03657342BOSTON-1Updated Oct 27, 2025Results posted

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

A Phase 3 interventional study of Liposomal Cyclosporine A and standard of care in Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant and Lung Transplant Rejection, sponsored by Zambon SpA. Completed at 39 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-27.

Sponsored by Zambon SpA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Bronchiolitis Obliterans with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Bronchiolitis Obliterans · United States.

Enrollment
4th of 25
62 · median 19
Started
2019
with 2 others
Phase 3
5 of 34
none open now
Registered
22nd of 34
by date
Lead sponsor
3 of 34
Zambon SpA

Among the 34 studies in Bronchiolitis Obliterans with a site in United States, this one is the 4th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 3, and was the 22nd registered.

Bronchiolitis Obliterans

82 studies on the registry are indexed under Bronchiolitis Obliterans; 9 are open to participants now.

Browse Bronchiolitis Obliterans studies →

Open to participants now

5 of the 34 studies in Bronchiolitis Obliterans with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Bronchiolitis Obliterans studies recruiting now, 5 set no upper age limit and 4 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Bronchiolitis Obliterans with a site in United States, or all of them as a file.
02

Study summary

The objective of this trial is to assess the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) as add-on therapy to standard of care (SoC) as compared to SoC alone in single lung transplant recipients with chronic lung allograft dysfunction (CLAD)-bronchiolitis obliterans syndrome (BOS).

Read the detailed description

BOSTON-1 was a Phase III, prospective, multicenter, randomized, open-label, controlled clinical trial of L-CsA for the treatment of BOS in adults diagnosed with CLAD-BOS following single lung transplant.

Eligible patients were randomized to receive either L-CsA (5 mg) via the PARI eFlow® Device (L-CsA eFlow) twice daily plus SoC treatment or SoC alone for a period of 48 weeks.

Regardless of treatment allocation, all patients continued to receive their SoC regimen for maintenance of the lung allograft. Maintenance immunosuppressive therapy including tacrolimus, a second agent such as, but not limited to, MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent was administered according to institutional standards.

Up to 11 study visits (screening, V1 through V10) were planned. Spirometry was measured at all visits according to American Thoracic Society/European Respiratory Society 2005 guidelines. Spirometry measurements on-site were performed by pulmonary function technicians, respiratory therapists, or physiotherapists who were blinded to each patient's study treatment assignment.

Safety assessments at every study visit included physical examination, vital signs, adverse event (AE) reporting, and clinical laboratory tests. Acute tolerability of L-CsA was assessed by spirometry before and 1 hour and 4 hours after inhalation of L-CsA at initial dosing.

All patients who completed the study were eligible to continue in an open-label extension trial of L-CsA (BOSTON-3 [Study BT-L-CsA-303-FU]).

03

Conditions studied

  • Bronchiolitis Obliterans
  • Chronic Rejection of Lung Transplant
  • Lung Transplant Rejection
  • Lung Transplant; Complications
  • Lung Transplant Failure and Rejection
  • Chronic Lung Allograft Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients ≥ 18 years who received a single lung transplant at least 12 months prior to Screening.
  2. Patients with BOS diagnosis defined as CLAD-BOS phenotype with:

    1. Screening between 85-51% of personal best FEV1 value post-transplant OR
    2. Screening FEV1 >85% of personal best FEV1 associated with EITHER a ≥ 200 mL decrease in FEV1 in the previous 12 months OR according to medical history showing BOS progression.
  3. Diagnosis of CLAD-BOS must have been made at least 12 months after lung transplantation and

    1. within 12 months prior to the screening visit OR
    2. more than 12 months from screening and patient must have shown a decline in FEV1 ≥ 200ml in the previous 12 months before screening, which was not due to acute infection or acute organ rejection.
  4. Patients in whom the diagnosis of BOS had been confirmed by the elimination of other possible causes of obstructive or restrictive lung disease (CLAD - RAS phenotype, see Protocol Specific Definitions).
  5. Patients should have been on a maintenance regimen of agents including tacrolimus, a second agent such as but not limited to mycophenolate mofetil (MMF) or azathioprine, and a systemic such as prednisone as third agent. The regimen must have been stable within 4 weeks prior to randomization with respect to the therapeutic agents. In case a patient was also receiving concomitant azithromycin for prophylaxis or treatment of BOS in addition to the previously described immunosuppressive regimen, azithromycin must have been on a stable regimen for at least 4 weeks prior to randomization.
  6. Patients capable of understanding the purposes and risks of the clinical trial, who had given written and agreed to comply with the clinical trial requirements/visit schedules, and who were capable of aerosol inhalation. Patients must have consented to retrieve prespecified data from the historic medical record (e.g., information related to the transplant surgery; spirometry data; medication use).
  7. Women of must have had a negative serum or urine pregnancy test within 7 days prior to randomization and must agree to use one of the methods of listed in Appendix II of the Protocol through their End of Study (EoS) Visit.
  8. Patients had no concomitant diagnoses that were considered fatal within one year (12 months) of Screening.

Exclusion criteria

Exclusion Criteria:

  1. Patients with confirmed other causes for loss of lung function, such as acute infection, acute rejection, restrictive allograft syndrome (CLAD - RAS phenotype, see Protocol Specific Definition ), etc.
  2. Patients with acute antibody-mediated rejection at Screening. In this context, clinically stable patients (as judged by the Investigator) with detectable levels of donor specific antibodies (DSA) at the Screening Visit were eligible for the study.
  3. Active acute bacterial, viral, or fungal infection not successfully resolved at least 4 weeks prior to the Screening Visit. Patients with chronic infection or colonization who were clinically stable as per judgement of the Investigator are eligible for the study.
  4. Mechanical ventilation (including CPAP) within 12 weeks prior to Randomization.
  5. Patients with uncontrolled hypertension.
  6. Patient had baseline resting oxygen saturation of \< 89% on room air or use of supplemental oxygen at rest.
  7. Evidence of functional airway stenosis (e.g., bronchomalacia/tracheomalacia, airway stents, or airways requiring balloon dilatations to maintain patency) with onset after the initial diagnosis of BOS and ongoing at Screening and/or Baseline Visit.
  8. Known to L-CsA or to cyclosporine A.
  9. Patients with chronic renal failure, defined as serum creatinine > 2.5 mg/dL at screening, or requiring chronic dialysis.
  10. Patients with liver disease and serum > 3-fold or transaminases > 2.5 upper limit of normal range.
  11. Patients with active within the previous 2 years, including post-transplant lymphoproliferative disorder, with the exception of treated, localized basal and squamous cell carcinomas.
  12. Pregnant women or women who were unwilling to use appropriate to avoid pregnancy through their End of Study (EoS) Visit.
  13. Women who were currently breastfeeding.
  14. Receipt of an drug as part of a clinical trial within 4 weeks prior to the Screening Visit. This was defined as any treatment that was implemented under an Investigational New Drug (IND) or compassionate use.
  15. Patients who had received extracorporeal photophoresis (ECP) for treatment of BOS within 1 month prior to Randomization.
  16. Patients who were currently participating in an interventional clinical trial.
  17. Psychiatric disorders or altered mental status precluding understanding of the process and/or completion of the necessary procedures.
  18. Any co-existing medical condition that in the Investigator's judgment would substantially increase the risk associated with the patient's participation in the clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    L-CsA treatment plus SoC

    Liposomal Cyclosporine A 5 mg twice daily for 48 weeks + Standard of Care Therapy

    Drug: Liposomal Cyclosporine A

  • Active comparator
    Control treatment

    In this arm only the standard of care is administered. Standard of care is a maintenance regimen of immunosuppressive agents.

    Drug: standard of care

Interventions

  • This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

    Also known as: L-CsA

  • Drugstandard of care

    Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.

    Also known as: SoC

06

What researchers measure

Primary outcomes

  1. Mean Change in FEV1 (L) From Baseline to Week 48

    FEV1 is the Forced Expiratory Volume in One Second. For FEV1 were considered primary the data collected from the on site COMPACT study spirometer. Baseline is the mean of the best FEV1 obtained with the study spirometer at Screening Visit and the pre-randomization best FEV1 obtained at the Baseline Visit (V1).The primary efficacy analysis was carried out using a Linear Mixed Model (LMM) for repeated measures, using all observed available FEV1 measurements. In case of death or re-transplantation events, FEV1 was imputed as zero at each nominal day post event. PS: Estimates are from a LMM on the response variable with factors for time splines, treatment, the interactions of time splines by treatment, baseline FEV1, the interactions of time splines with baseline FEV1, region, underlying indication for lung transplant (COPD vs all others), use of azithromycin at randomization, and time as random effect.

    Time frame: Week 48 (V9)

Secondary outcomes

  1. Mean Change in FEV1/FVC From Baseline to Week 48

    Forced Expiratory Volume in One Second on Forced Vital Capacity. It was analysed in the FAS using a LMM for repeated measurements and COMPACT data, with baseline FEV1/FVC among covariates. In case of death or re- transplantation events, FEV1/FVC was imputed as zero at each nominal day post event. FEV1/FVC is a calculated ratio used to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity.

    Time frame: Week 48

  2. Time to Progression of Bronchiolitis Obliterans Syndrome (BOS)

    The progression of BOS is defined as the earliest of the following: * Absolute decrease from baseline in FEV1 by at least 10% or 200 mL and a decrease in FEV1/FVC by at least 5% (if a patient had an event that met this criterion for progression of BOS, progression of BOS must have been confirmed by measurements that were taken with COMPACT spirometer at least 2 weeks apart) OR * Worsening of BOS grade, OR * Re-transplantation, OR * Death from respiratory failure. Rules for censoring progression of BOS are set. More than one type of event might correspond to the event of BOS progression (even those occurring on the same date). In case progression of BOS was defined by more than one criterion on different dates, the earliest event date was considered, i.e., the date closer to randomization was used as the progression date.

    Time frame: From date of randomization until the date of first documented progression of BOS, or date of retransplantation, or date of death from respiratory failure, whichever came first, assessed up to 48 weeks.

Other outcomes

  1. Number of Patients With Adverse Events (AE)

    An AE is an untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine.

    Time frame: Baseline through study completion (week 48)

  2. Acute Tolerability of L-CsA: Change From Pre-dose to 1 hr and 4h Post-dose

    Acute tolerability of IMP (L-CsA) during initial dosing was determined by measuring spirometry 1 hour and 4 hours after treatment. The FEV1 was measured prior to dosing with L-CsA. A decline of ≥20% associated with symptoms could have warranted IMP discontinuation. Parameters reflecting acute tolerability of IMP were: spirometry, cough, or dyspnea.

    Time frame: Baseline through study completion Week 48

07

Results

Posted Oct 27, 2025

Participant flow

The study randomized 62 patients globally from 26Mar2019 to 16Apr2024.

Participant flow — Overall Study
MilestoneL-CsA treatment plus SoCSoC alone
Started3230
Fas3230
Saf3230
Pps2119
Completed2023
Not completed127
Withdrew: Adverse event, including sae/death63
Withdrew: Withdrawal by subject44
Withdrew: Patient withdrawn by the sponsor due to use of cyclosporine a during trial (not allowed)10
Withdrew: Pi withdrew patient due to the his/her unstable clinical condition10

Outcome measures

PrimaryMean Change in FEV1 (L) From Baseline to Week 48

FEV1 is the Forced Expiratory Volume in One Second. For FEV1 were considered primary the data collected from the on site COMPACT study spirometer. Baseline is the mean of the best FEV1 obtained with the study spirometer at Screening Visit and the pre-randomization best FEV1 obtained at the Baseline Visit (V1).The primary efficacy analysis was carried out using a Linear Mixed Model (LMM) for repeated measures, using all observed available FEV1 measurements. In case of death or re-transplantation events, FEV1 was imputed as zero at each nominal day post event. PS: Estimates are from a LMM on the response variable with factors for time splines, treatment, the interactions of time splines by treatment, baseline FEV1, the interactions of time splines with baseline FEV1, region, underlying indication for lung transplant (COPD vs all others), use of azithromycin at randomization, and time as random effect.

Time frame:
Week 48 (V9)
Reported as:
Least squares mean · liters
Mean Change in FEV1 (L) From Baseline to Week 48
litersL-CsA treatment plus SoC (FAS)SoC alone (FAS)
Mean Change in FEV1 (L) From Baseline to Week 48-0.186 ± 0.3093-0.090 ± 0.2879
Statistical analysis
  • L-CsA treatment plus SoC (FAS) vs SoC alone (FAS) · Mixed Models Analysis · p = 0.7310 (1-sided p value.) · Ls mean difference: -0.095 · 95% CI -0.405 to 0.214
SecondaryMean Change in FEV1/FVC From Baseline to Week 48

Forced Expiratory Volume in One Second on Forced Vital Capacity. It was analysed in the FAS using a LMM for repeated measurements and COMPACT data, with baseline FEV1/FVC among covariates. In case of death or re- transplantation events, FEV1/FVC was imputed as zero at each nominal day post event. FEV1/FVC is a calculated ratio used to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity.

Time frame:
Week 48
Reported as:
Least squares mean · ratio
Mean Change in FEV1/FVC From Baseline to Week 48
ratioL-CsA treatment plus SoC (SAF)SoC alone (SAF)
Mean Change in FEV1/FVC From Baseline to Week 480.093 ± 0.23530.157 ± 0.2433
Statistical analysis
  • L-CsA treatment plus SoC (SAF) vs SoC alone (SAF) · Mixed Models Analysis · p = 0.8041 (1-sided p value) · Least suare mean difference: -0.064 · 95% CI -0.212 to 0.084
SecondaryTime to Progression of Bronchiolitis Obliterans Syndrome (BOS)

The progression of BOS is defined as the earliest of the following: * Absolute decrease from baseline in FEV1 by at least 10% or 200 mL and a decrease in FEV1/FVC by at least 5% (if a patient had an event that met this criterion for progression of BOS, progression of BOS must have been confirmed by measurements that were taken with COMPACT spirometer at least 2 weeks apart) OR * Worsening of BOS grade, OR * Re-transplantation, OR * Death from respiratory failure. Rules for censoring progression of BOS are set. More than one type of event might correspond to the event of BOS progression (even those occurring on the same date). In case progression of BOS was defined by more than one criterion on different dates, the earliest event date was considered, i.e., the date closer to randomization was used as the progression date.

Time frame:
From date of randomization until the date of first documented progression of BOS, or date of retransplantation, or date of death from respiratory failure, whichever came first, assessed up to 48 weeks.
Reported as:
Median · Weeks
Time to Progression of Bronchiolitis Obliterans Syndrome (BOS)
WeeksL-CsA treatment plus SoC (FAS)SoC alone (FAS)
Time to Progression of Bronchiolitis Obliterans Syndrome (BOS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • L-CsA treatment plus SoC (FAS) vs SoC alone (FAS) · Regression, Cox · p = 0.1559 (1-sided p value. Adjusted Hazard Ratio calculated using Cox proportional hazards model with covariates of Treatment, Baseline FEV1, with Efron's method of tie handling.) · Adjusted hazard ratio: 2.601 · 95% CI 0.408 to 16.585
Other pre-specifiedNumber of Patients With Adverse Events (AE)

An AE is an untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine.

Time frame:
Baseline through study completion (week 48)
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events (AE)
ParticipantsL-CsA treatment plus SoC (SAF)SoC alone (SAF)
No of patients with any AE3225
No. of patients with any TEAE leading to discontinuation of study treatment82
No. of patients with any TEAE leading to study discontinuation63
No. of patients with any TEAE leading to death63
No. of patients with any TEAE of Grade 1 severity (Mild)2222
No. of patients with any TEAE of Grade 2 severity (Moderate)1412
No. of patients with any TEAE of Grade 3 severity (severe)158
No. of patients with any study treatment-related TEAE11NA
No. of patients with any serious TEAE2014
No. of patients with any serious treatment-related TEAE3NA
Other pre-specifiedAcute Tolerability of L-CsA: Change From Pre-dose to 1 hr and 4h Post-dose

Acute tolerability of IMP (L-CsA) during initial dosing was determined by measuring spirometry 1 hour and 4 hours after treatment. The FEV1 was measured prior to dosing with L-CsA. A decline of ≥20% associated with symptoms could have warranted IMP discontinuation. Parameters reflecting acute tolerability of IMP were: spirometry, cough, or dyspnea.

Time frame:
Baseline through study completion Week 48
Reported as:
Mean · Liters
Acute Tolerability of L-CsA: Change From Pre-dose to 1 hr and 4h Post-dose
LitersL-CsA treatment plus SoC (SAF)
1 hr Post-dose-0.022 ± 0.0663
4 hr Post-dose-0.019 ± 0.0701

Adverse events

Collected over Permanent assessment throughout the complete clinical trial period, from baseline (Week 0, Day 1, V1) till week 48 (V9). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
L-CsA treatment plus SoC (SAF)6/32 (18.8%)20/32 (62.5%)28/32 (87.5%)
SoC alone (SAF)3/30 (10%)14/30 (46.7%)17/30 (56.7%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventL-CsA treatment plus SoC (SAF)SoC alone (SAF)
COVID-19Infections and infestations7/325/30
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/320/30
Cardiac failure congestiveCardiac disorders3/320/30
Acute kidney injuryRenal and urinary disorders3/320/30
COVID-19 pneumoniaInfections and infestations2/321/30
Pneumonia pseudomonalInfections and infestations2/320/30
Septic shockInfections and infestations2/320/30
DyspnoeaRespiratory, thoracic and mediastinal disorders2/320/30
Respiratory failureRespiratory, thoracic and mediastinal disorders2/321/30
Cardiac failureCardiac disorders2/320/30
Most frequent other events
Most frequent other events
EventL-CsA treatment plus SoC (SAF)SoC alone (SAF)
COVID-19Infections and infestations7/325/30
CoughRespiratory, thoracic and mediastinal disorders5/322/30
DyspnoeaRespiratory, thoracic and mediastinal disorders4/324/30
HypertensionVascular disorders2/324/30
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/320/30
BronchitisInfections and infestations3/321/30
Oedema peripheralGeneral disorders3/321/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)L-CsA treatment plus SoC (SAF)SoC alone (SAF)Total
<=18 years000
Between 18 and 65 years9514
>=65 years232548
Age, Continuous
Age, Continuous(years)L-CsA treatment plus SoC (SAF)SoC alone (SAF)Total
Mean66.9 ± 7.2069.3 ± 5.2868.0 ± 6.41
Sex: Female, Male
Sex: Female, Male(Participants)L-CsA treatment plus SoC (SAF)SoC alone (SAF)Total
Female101323
Male221739
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)L-CsA treatment plus SoC (SAF)SoC alone (SAF)Total
Hispanic or Latino314
Not Hispanic or Latino292958
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)L-CsA treatment plus SoC (SAF)SoC alone (SAF)Total
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American246
White282553
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)L-CsA treatment plus SoC (SAF)SoC alone (SAF)Total
United States212041
United Kingdom123
Israel246
Germany303
Spain549
08

Study locations

39 sites
  • Banner Health
    Phoenix, Arizona 85013, United States
  • Norton Thoracic Institute at St. Joseph's Hospital
    Phoenix, Arizona 85013, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Stanford University Hospital
    Palo Alto, California 94305, United States
  • UC San Francisco
    San Francisco, California 94143, United States
  • University of Florida Medical Center
    Gainesville, Florida 32608, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Indiana University Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
  • University of Kentucky Albert B. Chandler Hospital
    Lexington, Kentucky 40508, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University Hospital
    Baltimore, Maryland 21287, United States
  • 110
    St Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • 113
    New York, New York 22042, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • 119
    Columbus, Ohio 43210, United States
  • 108
    Philadelphia, Pennsylvania 19104, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor St. Luke's Medical Center
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, France
  • Hannover Medical School - MHH Klinik für Pneumologie
    Hanover, Germany
  • LMU Klinikum Großhadern
    Munich, Germany
  • Rabin Medical Center
    Petah Tikva, Israel
  • Complexo Hospitalario de A Coruna
    A Coruña, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Puerta de Hierro
    Madrid, Spain
  • Hospital Marques de Valdecilla
    Santander, Spain
  • Hospital Universitario y Politécnico La Fe
    Valencia, Spain
  • Royal Papworth Hospital NHS Foundation Trust
    Cambridge, United Kingdom
  • University Hospital of South Manchester NHS Foundation Trust
    Manchester, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Apr 2024, 60 months.

Results were first posted in Oct 2025, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2018
First posted
Sep 5, 2018
StartActual
Mar 26, 2019
Primary completionActual
Apr 16, 2024
CompletionActual
Apr 16, 2024
Results first posted
Oct 27, 2025
Last update
Oct 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03657342
Lead sponsor
Zambon SpA
Responsible party
Sponsor
First posted
Sep 5, 2018
Start date
Mar 26, 2019
Primary completion
Apr 16, 2024
Completion
Apr 16, 2024
Results posted
Oct 27, 2025
Last update
Oct 27, 2025

Study contacts

Paola Castellani, MD
study director · Zambon SpA, Chief Medical Officer and R&D

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion